FDA Cites Latisse Web Site For Implying Eyelash Growth Drug Is A Cosmetic
This article was originally published in The Rose Sheet
Executive Summary
Allergan's consumer Web site for its eyelash growth drug Latisse certainly caught FDA's eye, leading the agency to issue a Sept. 10 "untitled" letter that cautions against promoting a drug like a cosmetic
You may also be interested in...
Coty/Rimmel Targeted With Suit Over Lash Accelerator Claims
Lawsuit seeking class-action status against Coty alleges that lengthening and multiplying claims for the firm’s Rimmel London Lash Accelerator are “false, misleading and are reasonably likely to deceive the public.”
FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims
An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.
FDA’s Warning To Lash-Growth Firm Shows Risks In Third-Party Claims
An April 18 FDA warning letter to Lifetech Resources LLC demonstrates that cosmetics firms will be held accountable when their websites feature third-party claims and testimonials that cross into drug marketing territory.